cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia]
cyclosporine
RxCUI: 2590613
What the CMS Formulary Data Shows for cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia]
Per the CMS 2026 Part D formulary file, cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] (RxNorm concept RXCUI 2590613, generic name cyclosporine) appears on 8 distinct formulary files spanning 152 Medicare Part D plan offerings - 3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.
Real-world access to cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] depends on utilization management as much as tier placement: 75% of covering formularies require prior authorization. 0% require step therapy. 37.5% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 492,479 Part D beneficiaries filled cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] in 2023, with total plan-and-beneficiary spending of $1,501,664,198 and an average per-beneficiary annual cost of $3,049.19. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] today.
Coverage Details
- Formularies covering
- 8
- Plans covering
- 152
- Coverage rate
- 3%
- Tier range
- Tier 5, Specialty
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 75% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 37.5% of formularies
2023 Medicare Spending
- Beneficiaries
- 492,479
- Total spending
- $1,501,664,198
- Avg per beneficiary
- $3,049.19
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] covered by Medicare Part D?
Yes, cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] is covered by 152 Medicare Part D plans (3% of all Part D formularies).
What tier is cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] on Medicare Part D plans?
cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.
Does cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] require prior authorization?
75% of Part D formularies require prior authorization for cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia]. Step therapy: 0%. Quantity limits: 37.5%.
How much does Medicare spend on cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia]?
In 2023, total Medicare Part D spending on cyclosporine 1 MG/ML Ophthalmic Suspension [Verkazia] was $1,501,664,198, covering 492,479 beneficiaries. The average spend per beneficiary was $3,049.19.
Read our methodology - how this data is sourced, computed, and verified.